-
Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells Cancer Cell (IF 50.3) Pub Date : 2024-02-29 Manuel Colucci, Sara Zumerle, Silvia Bressan, Federico Gianfanti, Martina Troiani, Aurora Valdata, Mariantonietta D’Ambrosio, Emiliano Pasquini, Angelica Varesi, Francesca Cogo, Simone Mosole, Cristina Dongilli, Maria Andrea Desbats, Liliana Contu, Ajinkya Revankdar, Jingjing Chen, Madhuri Kalathur, Maria Luna Perciato, Rossella Basilotta, Laczko Endre, Stefan Schauer, Alaa Othman, Ilaria Guccini,
Cellular senescence can exert dual effects in tumors, either suppressing or promoting tumor progression. The senescence-associated secretory phenotype (SASP), released by senescent cells, plays a crucial role in this dichotomy. Consequently, the clinical challenge lies in developing therapies that safely enhance senescence in cancer, favoring tumor-suppressive SASP factors over tumor-promoting ones
-
Unleashing a safe and potent pro-senescence anti-tumor strategy Cancer Cell (IF 50.3) Pub Date : 2024-02-29 Shasha Chen, Beicheng Sun, Zhongjun Dong
-
PDGFRα+ITGA11+ fibroblasts foster early-stage cancer lymphovascular invasion and lymphatic metastasis via ITGA11-SELE interplay Cancer Cell (IF 50.3) Pub Date : 2024-02-29 Hanhao Zheng, Mingjie An, Yuming Luo, Xiayao Diao, Wenlong Zhong, Mingrui Pang, Yan Lin, Jiancheng Chen, Yuanlong Li, Yao Kong, Yue Zhao, Yina Yin, Le Ai, Jian Huang, Changhao Chen, Tianxin Lin
Cancer-associated fibroblasts (CAFs) exhibit considerable heterogeneity in advanced cancers; however, the functional annotation and mechanism of CAFs in early-stage cancers remain elusive. Utilizing single-cell RNA sequencing and spatial transcriptomic, we identify a previously unknown PDGFRαITGA11 CAF subset in early-stage bladder cancer (BCa). Multicenter clinical analysis of a 910-case cohort confirms
-
Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients Cancer Cell (IF 50.3) Pub Date : 2024-02-29 Andrea J. Radtke, Ekaterina Postovalova, Arina Varlamova, Alexander Bagaev, Maria Sorokina, Olga Kudryashova, Mark Meerson, Margarita Polyakova, Ilia Galkin, Viktor Svekolkin, Sergey Isaev, Daniil Wiebe, Anna Sharun, Alexander Sarachakov, Grigory Perelman, Yaroslav Lozinsky, Ziv Yaniv, Bradley C. Lowekamp, Emily Speranza, Li Yao, Stefania Pittaluga, Arthur L. Shaffer III, Danny Jonigk, James D. Phelan
Follicular lymphoma (FL) is a generally incurable malignancy that evolves from developmentally blocked germinal center (GC) B cells. To promote survival and immune escape, tumor B cells undergo significant genetic changes and extensively remodel the lymphoid microenvironment. Dynamic interactions between tumor B cells and the tumor microenvironment (TME) are hypothesized to contribute to the broad
-
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer Cancer Cell (IF 50.3) Pub Date : 2024-02-22 Xinyuan Tong, Ayushi S. Patel, Eejung Kim, Hongjun Li, Yueqing Chen, Shuai Li, Shengwu Liu, Julien Dilly, Kevin S. Kapner, Ningxia Zhang, Yun Xue, Laura Hover, Suman Mukhopadhyay, Fiona Sherman, Khrystyna Myndzar, Priyanka Sahu, Yijun Gao, Fei Li, Fuming Li, Zhaoyuan Fang, Yujuan Jin, Juntao Gao, Minglei Shi, Satrajit Sinha, Luonan Chen, Yang Chen, Thian Kheoh, Wenjing Yang, Itai Yanai, Andre L. Moreira
KRAS inhibitors (adagrasib and sotorasib) have shown clinical promise in targeting -mutated lung cancers; however, most patients eventually develop resistance. In lung patients with adenocarcinoma with and / co-mutations, we find an enrichment of the squamous cell carcinoma gene signature in pre-treatment biopsies correlates with a poor response to adagrasib. Studies of -deficient and lung cancer mouse
-
Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment Cancer Cell (IF 50.3) Pub Date : 2024-02-22 Xue-Yan He, Yuan Gao, David Ng, Evdokia Michalopoulou, Shanu George, Jose M. Adrover, Lijuan Sun, Jean Albrengues, Juliane Daßler-Plenker, Xiao Han, Ledong Wan, Xiaoli Sky Wu, Longling S. Shui, Yu-Han Huang, Bodu Liu, Chang Su, David L. Spector, Christopher R. Vakoc, Linda Van Aelst, Mikala Egeblad
Chronic stress is associated with increased risk of metastasis and poor survival in cancer patients, yet the reasons are unclear. We show that chronic stress increases lung metastasis from disseminated cancer cells 2- to 4-fold in mice. Chronic stress significantly alters the lung microenvironment, with fibronectin accumulation, reduced T cell infiltration, and increased neutrophil infiltration. Depleting
-
Revisiting TNM staging for EBV-related nasopharyngeal carcinoma Cancer Cell (IF 50.3) Pub Date : 2024-02-22 Michael Dennis, Robert Haddad
-
Characterization of the generic mutant p53-rescue compounds in a broad range of assays Cancer Cell (IF 50.3) Pub Date : 2024-02-22 Shujun Xiao, Fangfang Shi, Huaxin Song, Jingyi Cui, Derun Zheng, Hesong Zhang, Kai Tan, Jiaqi Wu, Xueqin Chen, Jiale Wu, Yigang Tang, Yuting Dai, Min Lu
-
Vascular characterization reveals immunomodulatory targets for brain metastases Cancer Cell (IF 50.3) Pub Date : 2024-02-15 Roberta Lugano, Anna Dimberg
-
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade Cancer Cell (IF 50.3) Pub Date : 2024-02-15 Barzin Y. Nabet, Habib Hamidi, Myung Chang Lee, Romain Banchereau, Stefanie Morris, Leah Adler, Velimir Gayevskiy, Ahmed M. Elhossiny, Minu K. Srivastava, Namrata S. Patil, Kiandra A. Smith, Rajiv Jesudason, Caleb Chan, Patrick S. Chang, Matthew Fernandez, Sandra Rost, Lisa M. McGinnis, Hartmut Koeppen, Carl M. Gay, John D. Minna, John V. Heymach, Joseph M. Chan, Charles M. Rudin, Lauren A. Byers,
Atezolizumab (anti-PD-L1), combined with carboplatin and etoposide (CE), is now a standard of care for extensive-stage small-cell lung cancer (ES-SCLC). A clearer understanding of therapeutically relevant SCLC subsets could identify rational combination strategies and improve outcomes. We conduct transcriptomic analyses and non-negative matrix factorization on 271 pre-treatment patient tumor samples
-
Re-inventing a better wheel? Serplulimab for squamous cell lung cancer Cancer Cell (IF 50.3) Pub Date : 2024-02-12 Derek De-Rui Huang, James Chih-Hsin Yang
-
Envision the future of precision medicine in pediatric cancer Cancer Cell (IF 50.3) Pub Date : 2024-02-12 Y, ., A, ., , D, e, C, l, e, r, c, k
-
The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells Cancer Cell (IF 50.3) Pub Date : 2024-02-12 Ning-Ning Liu, Cheng-Xiang Yi, Lu-Qi Wei, Jin-An Zhou, Tong Jiang, Cong-Cong Hu, Lu Wang, Yuan-Yuan Wang, Yun Zou, Yi-Kai Zhao, Le-Le Zhang, Ya-Ting Nie, Yi-Jing Zhu, Xin-Yao Yi, Ling-Bing Zeng, Jing-Quan Li, Xiao-Tian Huang, Hong-Bin Ji, Zisis Kozlakidis, Lin Zhong, Christopher Heeschen, Xiao-Qi Zheng, Changbin Chen, Peng Zhang, Hui Wang
-
Precision treatment in advanced hepatocellular carcinoma Cancer Cell (IF 50.3) Pub Date : 2024-02-12 Xupeng Yang, Chen Yang, Shu Zhang, Haigang Geng, Andrew X. Zhu, René Bernards, Wenxin Qin, Jia Fan, Cun Wang, Qiang Gao
The past decade has witnessed significant advances in the systemic treatment of advanced hepatocellular carcinoma (HCC). Nevertheless, the newly developed treatment strategies have not achieved universal success and HCC patients frequently exhibit therapeutic resistance to these therapies. Precision treatment represents a paradigm shift in cancer treatment in recent years. This approach utilizes the
-
Actomyosin-Mediated Cellular Tension Drives Increased Tissue Stiffness and β-Catenin Activation to Induce Epidermal Hyperplasia and Tumor Growth Cancer Cell (IF 50.3) Pub Date : 2024-02-12 Michael S. Samuel, Jose I. Lopez, Ewan J. McGhee, Daniel R. Croft, David Strachan, Paul Timpson, June Munro, Ewald Schröder, Jing Zhou, Valerie G. Brunton, Nick Barker, Hans Clevers, Owen J. Sansom, Kurt I. Anderson, Valerie M. Weaver, Michael F. Olson
-
Benchmarking mismatch repair testing for patients with cancer receiving immunotherapy Cancer Cell (IF 50.3) Pub Date : 2024-02-12 Elias Bou Farhat, Elio Adib, Melissa Daou, Abdul Rafeh Naqash, Ursula Matulonis, Kimmie Ng, David J. Kwiatkowski, Lynette M. Sholl, Amin H. Nassar
-
Inosine induces stemness features in CAR-T cells and enhances potency Cancer Cell (IF 50.3) Pub Date : 2024-01-25 Dorota D. Klysz, Carley Fowler, Meena Malipatlolla, Lucille Stuani, Katherine A. Freitas, Yiyun Chen, Stefanie Meier, Bence Daniel, Katalin Sandor, Peng Xu, Jing Huang, Louai Labanieh, Vimal Keerthi, Amaury Leruste, Malek Bashti, Janette Mata-Alcazar, Nikolaos Gkitsas, Justin A. Guerrero, Chris Fisher, Sunny Patel, Kyle Asano, Shabnum Patel, Kara L. Davis, Ansuman T. Satpathy, Steven A. Feldman, Elena
-
Unlocking CAR T cell potential: Inosine-induced stemness and enhanced potency Cancer Cell (IF 50.3) Pub Date : 2024-01-25 Xingying Zhang, Haoyi Wang
Adenosine (Ado) drives immune suppression in the tumor microenvironment. In this issue of Cancer Cell, Klysz et al. investigate Ado-mediated immunosuppression. Overexpression of Ado deaminase (ADA-OE), metabolizing Ado to inosine (INO), induces stemness and improves CAR T cell functionality. Likewise, exposure to INO enhances CAR T cells’ function and induces stemness features.
-
Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes Cancer Cell (IF 50.3) Pub Date : 2024-01-25 Simon Heeke, Carl M. Gay, Marcos R. Estecio, Hai Tran, Benjamin B. Morris, Bingnan Zhang, Ximing Tang, Maria Gabriela Raso, Pedro Rocha, Siqi Lai, Edurne Arriola, Paul Hofman, Veronique Hofman, Prasad Kopparapu, Christine M. Lovly, Kyle Concannon, Luana Guimaraes De Sousa, Whitney Elisabeth Lewis, Kimie Kondo, Xin Hu, Azusa Tanimoto, Natalie I. Vokes, Monique B. Nilsson, Allison Stewart, Maarten Jansen
-
Interrogation of endothelial and mural cells in brain metastasis reveals key immune-regulatory mechanisms Cancer Cell (IF 50.3) Pub Date : 2024-01-18 Leire Bejarano, Annamaria Kauzlaric, Eleni Lamprou, Joao Lourenco, Nadine Fournier, Michelle Ballabio, Roberto Colotti, Roeltje Maas, Sabine Galland, Matteo Massara, Klara Soukup, Johanna Lilja, Jean-Philippe Brouland, Andreas F. Hottinger, Roy T. Daniel, Monika E. Hegi, Johanna A. Joyce
-
Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer Cancer Cell (IF 50.3) Pub Date : 2024-01-18 Lena Cords, Stefanie Engler, Martina Haberecker, Jan Hendrik Rüschoff, Holger Moch, Natalie de Souza, Bernd Bodenmiller
-
Refining the 8th edition TNM classification for EBV related nasopharyngeal carcinoma Cancer Cell (IF 50.3) Pub Date : 2024-01-18 Xiao-Jing Du, Gao-Yuan Wang, Xiao-Dong Zhu, Ya-Qian Han, Feng Lei, Liang-Fang Shen, Kun-Yu Yang, Lei Chen, Yan-Ping Mao, Ling-Long Tang, Ling Li, Zheng Wu, Gui-Qiong Xu, Qin Zhou, Jing Huang, Rui Guo, Yuan Zhang, Xu Liu, Guan-Qun Zhou, Wen-Fei Li, Cheng Xu, Li Lin, Yu-Pei Chen, Fo-Ping Chen, Xiao-Yu Liang, Si-Yuan Chen, Shu-Qi Li, Chun-Yan Cui, Ji-Bin Li, Jian Ren, Ming-Yuan Chen, Li-Zhi Liu, Ying
-
Integrated proteogenomic characterization of glioblastoma evolution Cancer Cell (IF 50.3) Pub Date : 2024-01-11 Kyung-Hee Kim, Simona Migliozzi, Harim Koo, Jun-Hee Hong, Seung Min Park, Sooheon Kim, Hyung Joon Kwon, Seokjun Ha, Luciano Garofano, Young Taek Oh, Fulvio D'Angelo, Chan Il Kim, Seongsoo Kim, Ji Yoon Lee, Jiwon Kim, Jisoo Hong, Eun-Hae Jang, Bertrand Mathon, Anna-Luisa Di Stefano, Franck Bielle, Alice Laurenge, Alexey I. Nesvizhskii, Eun-Mi Hur, Jinlong Yin, Bingyang Shi, Youngwook Kim, Kyung-Sub
-
A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization Cancer Cell (IF 50.3) Pub Date : 2024-01-11 Clare Pacini, Emma Duncan, Emanuel Gonçalves, James Gilbert, Shriram Bhosle, Stuart Horswell, Emre Karakoc, Howard Lightfoot, Ed Curry, Francesc Muyas, Monsif Bouaboula, Chandra Sekhar Pedamallu, Isidro Cortes-Ciriano, Fiona M. Behan, Lykourgos-Panagiotis Zalmas, Andrew Barthorpe, Hayley Francies, Steve Rowley, Jack Pollard, Pedro Beltrao, Leopold Parts, Francesco Iorio, Mathew J. Garnett
-
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer Cancer Cell (IF 50.3) Pub Date : 2024-01-11 Danish Memon, Adam J. Schoenfeld, Darwin Ye, George Fromm, Hira Rizvi, Xiang Zhang, Mohamed Reda Keddar, Divij Mathew, Kyung Jin Yoo, Jingya Qiu, Jayon Lihm, Jayalaksmi Miriyala, Jennifer L. Sauter, Jia Luo, Andrew Chow, Umesh K. Bhanot, Caroline McCarthy, Chad M. Vanderbilt, Cailian Liu, Mohsen Abu-Akeel, Andrew J. Plodkowski, Nicholas McGranahan, Marta Łuksza, Benjamin D. Greenbaum, Taha Merghoub
-
Response to Bruton’s tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy Cancer Cell (IF 50.3) Pub Date : 2024-01-11 James D. Phelan, Sebastian Scheich, Jaewoo Choi, George W. Wright, Björn Häupl, Ryan M. Young, Sara A. Rieke, Martine Pape, Yanlong Ji, Henning Urlaub, Arnold Bolomsky, Carmen Doebele, Alena Zindel, Tanja Wotapek, Monica Kasbekar, Brett Collinge, Da Wei Huang, Zana A. Coulibaly, Vivian M. Morris, Xiaoxuan Zhuang, Julius C. Enssle, Xin Yu, Weihong Xu, Yandan Yang, Hong Zhao, Zhuo Wang, Andy D. Tran
-
Neoadjuvant radioimmunotherapy synergy in triple-negative breast cancer: Is microenvironment-guided patient selection on the horizon? Cancer Cell (IF 50.3) Pub Date : 2024-01-08 Simona F. Shaitelman, Wendy A. Woodward
Neoadjuvant chemotherapy plus immunotherapy for triple-negative breast cancer (TNBC) is associated with improved but incomplete response. In this issue of Cancer Cell, Shiao et al. characterize longitudinal biopsies from a window of opportunity study with single-cell RNA sequencing (scRNA-seq) and spatial proteomic profiling and elucidate synergy between radiotherapy (RT) and pembrolizumab.
-
Immune evasion by dormant disseminated cancer cells: A Fermi paradox? Cancer Cell (IF 50.3) Pub Date : 2024-01-08 Anna Adam-Artigues, Luis E. Valencia Salazar, Julio A. Aguirre-Ghiso
Rare disseminated tumor cells (DTCs) can persist after treatment in patients for years, and the immune system does not eliminate them. Goddard et al. propose that immune evasion by rare dormant DTCs is due to an improbability of contact imposed by large distances separating effector T cells and DTCs.
-
Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer Cancer Cell (IF 50.3) Pub Date : 2024-01-08 Stephen L. Shiao, Kenneth H. Gouin III, Nathan Ing, Alice Ho, Reva Basho, Aagam Shah, Richard H. Mebane, David Zitser, Andrew Martinez, Natalie-Ya Mevises, Bassem Ben-Cheikh, Regina Henson, Monica Mita, Philomena McAndrew, Scott Karlan, Armando Giuliano, Alice Chung, Farin Amersi, Catherine Dang, Heather Richardson, Wonwoo Shon, Farnaz Dadmanesh, Michele Burnison, Amin Mirhadi, Zachary S. Zumsteg,
Strategies are needed to better identify patients that will benefit from immunotherapy alone or who may require additional therapies like chemotherapy or radiotherapy to overcome resistance. Here we employ single-cell transcriptomics and spatial proteomics to profile triple negative breast cancer biopsies taken at baseline, after one cycle of pembrolizumab, and after a second cycle of pembrolizumab
-
Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies Cancer Cell (IF 50.3) Pub Date : 2024-01-08 Erica T. Goddard, Miles H. Linde, Shivani Srivastava, Grant Klug, Tamer B. Shabaneh, Santino Iannone, Candice A. Grzelak, Sydney Marsh, Alessandra I. Riggio, Ryann E. Shor, Ian L. Linde, Marissa Guerrero, Joshua R. Veatch, Annelise G. Snyder, Alana L. Welm, Stanley R. Riddell, Cyrus M. Ghajar
-
Distinct spatiotemporal dynamics of CD8+ T cell-derived cytokines in the tumor microenvironment Cancer Cell (IF 50.3) Pub Date : 2024-01-08 Mirjam E. Hoekstra, Maarten Slagter, Jos Urbanus, Mireille Toebes, Nadine Slingerland, Iris de Rink, Roelof J.C. Kluin, Marja Nieuwland, Ron Kerkhoven, Lodewyk F.A. Wessels, Ton N. Schumacher
-
Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy Cancer Cell (IF 50.3) Pub Date : 2024-01-04 Judith Wienke, Lindy L. Visser, Waleed M. Kholosy, Kaylee M. Keller, Marta Barisa, Evon Poon, Sophie Munnings-Tomes, Courtney Himsworth, Elizabeth Calton, Ana Rodriguez, Ronald Bernardi, Femke van den Ham, Sander R. van Hooff, Yvette A.H. Matser, Michelle L. Tas, Karin P.S. Langenberg, Philip Lijnzaad, Anne L. Borst, Elisa Zappa, Francisca J. Bergsma, Josephine G.M. Strijker, Bronte M. Verhoeven, Shenglin
-
A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004) Cancer Cell (IF 50.3) Pub Date : 2024-01-04 Caicun Zhou, Yanping Hu, Ekaterine Arkania, Saadettin Kilickap, Kejing Ying, Fei Xu, Lin Wu, Xiang Wang, Maksym Viguro, Tamta Makharadze, Hongmei Sun, Feng Luo, Jianhua Shi, Aimin Zang, Yueyin Pan, Zhendong Chen, Zhongyao Jia, Vladimer Kuchava, Ping Lu, Ling Zhang, Ying Cheng, Wenying Kang, Qingyu Wang, Haoyu Yu, Jing Li, Jun Zhu, on behalf of the ASTRUM-004 Investigators
-
Association of exercise with pan-cancer incidence and overall survival Cancer Cell (IF 50.3) Pub Date : 2024-01-04 Jessica A. Lavery, Paul C. Boutros, Daniel Knight, Tuomas Tammela, Chaya S. Moskowitz, Lee W. Jones
Abstract not available
-
Interferon-stimulated neutrophils as a predictor of immunotherapy response Cancer Cell (IF 50.3) Pub Date : 2024-01-04 Madeleine Benguigui, Tim J. Cooper, Prajakta Kalkar, Sagie Schif-Zuck, Ruth Halaban, Antonella Bacchiocchi, Iris Kamer, Abhilash Deo, Bar Manobla, Rotem Menachem, Jozafina Haj-Shomaly, Avital Vorontsova, Ziv Raviv, Chen Buxbaum, Petros Christopoulos, Jair Bar, Michal Lotem, Mario Sznol, Amiram Ariel, Shai S. Shen-Orr, Yuval Shaked
-
Gut epithelial Interleukin-17 receptor A signaling can modulate distant tumors growth through microbial regulation Cancer Cell (IF 50.3) Pub Date : 2023-12-28 Vidhi Chandra, Le Li, Olivereen Le Roux, Yu Zhang, Rian M. Howell, Dhwani N. Rupani, Seyda Baydogan, Haiyan D. Miller, Erick Riquelme, Joseph Petrosino, Michael P. Kim, Krishna P.L. Bhat, James R. White, Jay K. Kolls, Yuliya Pylayeva-Gupta, Florencia McAllister
-
Benchmarking mismatch repair testing for patients with cancer receiving immunotherapy Cancer Cell (IF 50.3) Pub Date : 2023-12-28 Elias Bou Farhat, Elio Adib, Melissa Daou, Elizabeth P. Henske, Abdul Rafeh Naqash, Ursula Matulonis, Kimmie Ng, David J. Kwiatkowski, Lynette M. Sholl, Amin H. Nassar
Abstract not available
-
EGFR-activated myofibroblasts promote metastasis of pancreatic cancer Cancer Cell (IF 50.3) Pub Date : 2023-12-28 Gianluca Mucciolo, Joaquín Araos Henríquez, Muntadher Jihad, Sara Pinto Teles, Judhell S. Manansala, Wenlong Li, Sally Ashworth, Eloise G. Lloyd, Priscilla S.W. Cheng, Weike Luo, Akanksha Anand, Ashley Sawle, Anna Piskorz, Giulia Biffi
-
Melanoma and microbiota: Current understanding and future directions Cancer Cell (IF 50.3) Pub Date : 2023-12-28 Bertrand Routy, Tanisha Jackson, Laura Mählmann, Christina K. Baumgartner, Martin Blaser, Allyson Byrd, Nathalie Corvaia, Kasey Couts, Diwakar Davar, Lisa Derosa, Howard C. Hang, Geke Hospers, Morten Isaksen, Guido Kroemer, Florent Malard, Kathy D. McCoy, Marlies Meisel, Sumanta Pal, Ze’ev Ronai, Eran Segal, Gregory D. Sepich-Poore, Fyza Shaikh, Randy F. Sweis, Giorgio Trinchieri, Marcel van den Brink
Over the last decade, the composition of the gut microbiota has been found to correlate with the outcomes of cancer patients treated with immunotherapy. Accumulating evidence points to the various mechanisms by which intestinal bacteria act on distal tumors and how to harness this complex ecosystem to circumvent primary resistance to immune checkpoint inhibitors. Here, we review the state of the microbiota
-
Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy Cancer Cell (IF 50.3) Pub Date : 2023-12-21 Sabina Kaczanowska, Tara Murty, Ahmad Alimadadi, Cristina F. Contreras, Caroline Duault, Priyanka B. Subrahmanyam, Warren Reynolds, Norma A. Gutierrez, Reema Baskar, Catherine J. Wu, Franziska Michor, Jennifer Altreuter, Yang Liu, Aashna Jhaveri, Vandon Duong, Hima Anbunathan, Claire Ong, Hua Zhang, Radim Moravec, Joyce Yu, Roshni Biswas, Stephen Van Nostrand, James Lindsay, Mina Pichavant, Elena Sotillo
-
GD2-CAR T cells in patients with osteosarcoma and neuroblastoma—it’s not only the T cells that matter Cancer Cell (IF 50.3) Pub Date : 2023-12-21 Azlann B Arnett, Andras Heczey
GD2-CAR T cells were safe and anti-tumor responses were limited. In this issue of Cancer Cell, Kaczanowska et al. find that apheresis products and peripheral blood at baseline contained significantly higher proportions of CXCR3+ monocytes in good expanders. CXCR3+ monocytes may influence CAR T cell function.
-
Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma Cancer Cell (IF 50.3) Pub Date : 2023-12-14 Yunfan Sun, Pin Wu, Zefan Zhang, Zejian Wang, Kaiqian Zhou, Minfang Song, Yuan Ji, Fenglin Zang, Limu Lou, Keqiang Rao, Pengxiang Wang, Yutong Gu, Jie Gu, Binbin Lu, Limeng Chen, Xiuqi Pan, Xiaojing Zhao, Lihua Peng, Dongbing Liu, Xiaofang Chen, Kui Wu, Penghui Lin, Liang Wu, Yulin Su, Min Du, Yingyong Hou, Xinrong Yang, Shuangjian Qiu, Yinghong Shi, Huichuan Sun, Jian Zhou, Xingxu Huang, David H.
-
Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites Cancer Cell (IF 50.3) Pub Date : 2023-12-11 Talya L. Dayton, Nicolas Alcala, Laura Moonen, Lisanne den Hartigh, Veerle Geurts, Lise Mangiante, Lisa Lap, Antonella F.M. Dost, Joep Beumer, Sonja Levy, Rachel S. van Leeuwaarde, Wenzel M. Hackeng, Kris Samsom, Catherine Voegele, Alexandra Sexton-Oates, Harry Begthel, Jeroen Korving, Lisa Hillen, Lodewijk A.A. Brosens, Sylvie Lantuejoul, Hans Clevers
-
NEN in a dish: A patient-derived organoid biobank illuminates potential novel therapeutic opportunities for neuroendocrine neoplasms Cancer Cell (IF 50.3) Pub Date : 2023-12-11 Stefanie Gerstberger, Karuna Ganesh
Neuroendocrine neoplasms are rare cancers with limited treatment options and preclinical models. In this issue of Cancer Cell, Dayton et al. establish a patient-derived tumor organoid biobank encompassing pulmonary low-grade neuroendocrine tumors (LNETs) and high-grade neuroendocrine carcinomas (LCNECs), identifying novel biomarker-dependent therapeutic vulnerabilities using niche perturbation and
-
ALKemy to enhance chimeric antigen receptor T cell immunotherapy for neuroblastoma Cancer Cell (IF 50.3) Pub Date : 2023-12-11 Marco Ruella
Chimeric antigen receptor (CAR) T cell immunotherapy in solid cancer is severely limited by the absence of ideal targets. In this issue of Cancer Cell, Bergaggio et al. find that anaplastic lymphoma kinase (ALK) inhibitors can enhance the function of ALK-specific CAR T cells against neuroblastoma by increasing target density in cancer cells.
-
B3GALT6 promotes dormant breast cancer cell survival and recurrence by enabling heparan sulfate-mediated FGF signaling Cancer Cell (IF 50.3) Pub Date : 2023-12-07 Amulya Sreekumar, Michelle Lu, Biswa Choudhury, Tien-chi Pan, Dhruv K. Pant, Matthew R. Lawrence-Paul, Christopher J. Sterner, George K. Belka, Takashi Toriumi, Brian A. Benz, Matias Escobar-Aguirre, Francesco E. Marino, Jeffrey D. Esko, Lewis A. Chodosh
-
Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers Cancer Cell (IF 50.3) Pub Date : 2023-11-30 Rami Yossef, Sri Krishna, Sivasish Sindiri, Frank J. Lowery, Amy R. Copeland, Jared J. Gartner, Maria R. Parkhurst, Neilesh B. Parikh, Kyle J. Hitscherich, Shoshana T. Levi, Praveen D. Chatani, Nikolaos Zacharakis, Noam Levin, Nolan R. Vale, Shirley K. Nah, Aaron Dinerman, Victoria K. Hill, Satyajit Ray, Alakesh Bera, Lior Levy, Steven A. Rosenberg
-
A road map for the treatment of pediatric diffuse midline glioma Cancer Cell (IF 50.3) Pub Date : 2023-11-30 Carl Koschmann, Wajd N. Al-Holou, Marta M. Alonso, Jamie Anastas, Pratiti Bandopadhayay, Tara Barron, Oren Becher, Rodrigo Cartaxo, Maria G. Castro, Chan Chung, Madison Clausen, Derek Dang, Robert Doherty, Ryan Duchatel, Matthew Dun, Mariella Filbin, Andrea Franson, Stefanie Galban, Marc Garcia Moure, Hugh Garton, Pruthvi Gowda, Joana Graca Marques, Cynthia Hawkins, Allison Heath, Esther Hulleman,
Recent clinical trials for H3K27-altered diffuse midline gliomas (DMGs) have shown much promise. We present a consensus roadmap and identify three major barriers: (1) refinement of experimental models to include immune and brain-specific components; (2) collaboration among researchers, clinicians, and industry to integrate patient-derived data through sharing, transparency, and regulatory considerations;
-
Genomic alterations driving precancerous to cancerous lesions in esophageal cancer development Cancer Cell (IF 50.3) Pub Date : 2023-11-30 Jiang Chang, Xuan Zhao, Yichen Wang, Tianyuan Liu, Ce Zhong, Yueqiong Lao, Shaosen Zhang, Han Liao, Fan Bai, Dongxin Lin, Chen Wu
-
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells Cancer Cell (IF 50.3) Pub Date : 2023-11-30 Elisa Bergaggio, Wei-Tien Tai, Andrea Aroldi, Carmen Mecca, Elisa Landoni, Manuel Nüesch, Ines Mota, Jasna Metovic, Luca Molinaro, Leyuan Ma, Diego Alvarado, Chiara Ambrogio, Claudia Voena, Rafael B. Blasco, Tongqing Li, Daryl Klein, Darrell J. Irvine, Mauro Papotti, Barbara Savoldo, Gianpietro Dotti, Roberto Chiarle
-
Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation Cancer Cell (IF 50.3) Pub Date : 2023-11-22 Chia-Chun Chen, Wendy Tran, Kai Song, Tyler Sugimoto, Matthew B. Obusan, Liang Wang, Katherine M. Sheu, Donghui Cheng, Lisa Ta, Grigor Varuzhanyan, Arthur Huang, Runzhe Xu, Yuanhong Zeng, Amirreza Borujerdpur, Nicholas A. Bayley, Miyako Noguchi, Zhiyuan Mao, Colm Morrissey, Eva Corey, Peter S. Nelson, Thomas G. Graeber
-
Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies Cancer Cell (IF 50.3) Pub Date : 2023-11-22 Luciano Nicosia, Gary J. Spencer, Nigel Brooks, Fabio M.R. Amaral, Naseer J. Basma, John A. Chadwick, Bradley Revell, Bettina Wingelhofer, Alba Maiques-Diaz, Oliver Sinclair, Francesco Camera, Filippo Ciceri, Daniel H. Wiseman, Neil Pegg, Will West, Tomasz Knurowski, Kris Frese, Karen Clegg, Victoria L. Campbell, James Cavet, Tim C.P. Somervaille
-
A longitudinal single-cell atlas of treatment response in pediatric AML Cancer Cell (IF 50.3) Pub Date : 2023-11-16 Sander Lambo, Diane L. Trinh, Rhonda E. Ries, Dan Jin, Audi Setiadi, Michelle Ng, Veronique G. Leblanc, Michael R. Loken, Lisa E. Brodersen, Fangyan Dai, Laura M. Pardo, Xiaotu Ma, Suzanne M. Vercauteren, Soheil Meshinchi, Marco A. Marra
-
The antitumor activities of anti-CD47 antibodies require Fc-FcγR interactions Cancer Cell (IF 50.3) Pub Date : 2023-11-16 Juan C. Osorio, Patrick Smith, David A. Knorr, Jeffrey V. Ravetch
-
Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer Cancer Cell (IF 50.3) Pub Date : 2023-11-02 Jessica E. Hawley, Aleksandar Z. Obradovic, Matthew C. Dallos, Emerson A. Lim, Karie Runcie, Casey R. Ager, James McKiernan, Christopher B. Anderson, Guarionex J. Decastro, Joshua Weintraub, Renu Virk, Israel Lowy, Jianhua Hu, Matthew G. Chaimowitz, Xinzheng V. Guo, Ya Zhang, Michael C. Haffner, Jeremy Worley, Mark N. Stein, Andrea Califano, Charles G. Drake
-
Bringing CAR T cell therapy trials to underserved populations Cancer Cell (IF 50.3) Pub Date : 2023-10-26 Hoda Badr, Rayne Rouce, Michael E. Scheurer, Premal Lulla, Martha Mims, Pavan Reddy
There is a critical need for equitable access to cell therapies in cancer treatment, particularly within public safety-net healthcare systems that serve minority and socioeconomically disadvantaged populations. We discuss how the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine is piloting a cell therapy program aimed at addressing cancer care disparities and has the potential
-
Mitochondrial control of antigen presentation in cancer cells Cancer Cell (IF 50.3) Pub Date : 2023-10-26 Ruth Soler-Agesta, Alberto Anel, Lorenzo Galluzzi
Cytotoxic T lymphocytes recognize and kill cancer cells when the latter present antigenic epitopes complexed with MHC class I molecules on their surface. In a recent Science paper, Mangalhara et al. show that alterations of the mitochondrial electron flow upregulate multiple factors involved in antigen presentation via a succinate-dependent epigenetic mechanism.
-
Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers Cancer Cell (IF 50.3) Pub Date : 2023-10-26 Evelyn Jiagge, Dexter X. Jin, Justin Y. Newberg, Tomin Perea-Chamblee, Kelly R. Pekala, Christopher Fong, Michele Waters, David Ma, Yvonne Dei-Adomakoh, Gilles Erb, Kanika S. Arora, Sophia L. Maund, Njoki Njiraini, Atara Ntekim, Susie Kim, Xuechun Bai, Marlene Thomas, Ronwyn van Eeden, Priti Hegde, Justin Jee, Jian Carrot-Zhang
-
Spatiotemporal genomic profiling of intestinal metaplasia reveals clonal dynamics of gastric cancer progression Cancer Cell (IF 50.3) Pub Date : 2023-10-26 Kie Kyon Huang, Haoran Ma, Roxanne Hui Heng Chong, Tomoyuki Uchihara, Benedict Shi Xiang Lian, Feng Zhu, Taotao Sheng, Supriya Srivastava, Su Ting Tay, Raghav Sundar, Angie Lay Keng Tan, Xuewen Ong, Minghui Lee, Shamaine Wei Ting Ho, Tom Lesluyes, Hassan Ashktorab, Duane Smoot, Peter Van Loo, Joy Shijia Chua, Kalpana Ramnarayanan, Patrick Tan
-
From intestinal metaplasia to gastric cancer: Witnessing the rise of evil over time and space Cancer Cell (IF 50.3) Pub Date : 2023-10-26 Cheng Zhang, Xi Jiao, Lin Shen
Intestinal metaplasia (IM) is a precancerous lesion associated with increased gastric cancer (GC) risk. However, the molecular characteristics and heterogeneity distinguishing the two stages remain unclear. Huang et al. provide a spatiotemporal insight into the transition from IM to GC, offering the potential for tailored precision prevention strategies for GC.